Noticias y vídeos - ALMIRALL

Almirall, S.A. (ALM) , the global biopharmaceutical company based in Barcelona, has announced its H1 2023 financial results. Financial highlights (€ rounded million) H1 2023 H1 2022 Variation Net Sales 466.1 436.6 6.8% Total EBITDA 101.3 107.6 -5.9% Net Income 12.0 27.3 -56.0% Normalized Net Income 11.6 27.6 -58.0% Summary of results Net Sales reached €466.1 MM, a +6.8% year-on-year increase boosted by the strong sales growth of the dermatology portfolio in Europe. Total EBITDA was at...

Almirall, S.A. (ALM) , a global biopharmaceutical company focused on medical dermatology, today announced that Ilumetri ® (tildrakizumab) significantly improved wellbeing in patients with moderate-to-severe plaque psoriasis achieving a wellbeing status similar to the general population 1 after 16 weeks, which was maintained up to week 28 ¡Error! Marcador no definido. . These first results of the POSITIVE study were presented in a poster at the 25 th World Congress of Dermatology, held in...

Psoriasis is a chronic dermatological disease that not only affects the skin but also their mental and social wellbeing. The disease has an impact on all aspects of daily lives and almost 77% of people living with psoriatic disease believe that it negatively affects their daily activities, causing a heavy physical, emotional and social burden that affects their mental health 1 and wellbeing 2 . Despite its high prevalence - approximately 1.52% of the UK population (1.01 million people estimated)...

Almirall S.A. (ALM) (the “ Company ”), a global biopharmaceutical company focused on skin health, has announced today the pricing and closing of its EUR 200,000,000 non-pre-emptive share capital increase announced yesterday evening (the “ Capital Increase ”) following completion of the accelerated book-building offering, which was carried out by J.P. Morgan and BNP PARIBAS as Joint Global Coordinators and Joint Bookrunners. As a result of the Capital Increase, the Company has raised a...

Almirall S.A. (ALM) (the “ Company ”), a global biopharmaceutical company focused on skin health, today announced the launch of a non pre- emptive share capital increase (the “ Capital Increase ”) for a total aggregate amount (including nominal value and share issue premium) of approximately EUR 200,000,000 by issuing new ordinary shares of the Company belonging to the same class and series as the outstanding shares (the “ New Shares ”) in consideration for cash contributions. The...

...

Almirall, S.A. (ALM) , the global biopharmaceutical company based in Barcelona, has announced its Q1 2023 financial results. Financial highlights (€ rounded million) Q1 2023 Q1 2022 Variation Net Sales 232.0 218.8 6.0% Total EBITDA 51.8 59.6 (13.1%) Net Income 7.7 20.4 (62.3%) Normalized Net Income 7.7 20.5 (62.4%) Summary of results Net Sales reached €232.0 MM, a +6% year-on-year increase underpinned by the strong sales growth of the dermatology portfolio in Europe. Total EBITDA was at...

Almirall S.A. (ALM) today announced results from a new secondary analysis from the Phase 3 clinical development program which showed patients receiving lebrikizumab who were assessed at 16 weeks experienced improved or cleared face or hand dermatitis, which can be particularly burdensome and stigmatizing because these areas are highly visible parts of the body. An additional secondary analysis further demonstrated lebrikizumab’s stable and long-lasting results at one year of treatment in...

Almirall, S.A. (ALM) , a global biopharmaceutical company focused on medical dermatology, announced today the publication of Week 16 and Week 52 results of ADvocate1 and ADvocate2 by the New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD), respectively. ADvocate1 and ADvocate2 are two identical 52-week randomized, double-blind, placebo-controlled, parallel-group, Phase 3 studies (NCT04146363 and NCT04178967), evaluating lebrikizumab as monotherapy in adult and...

Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, has announced its full-year 2022 financial results today. Financial highlights (€ rounded million) 2022 2021 Variation Total Revenues 878.5 836.5 5.0% Net Sales 863.2 827.2 4.4% Other Income 15.3 9.3 64.5% Gross Profit 572.9 571.3 0.3% % of sales 66.4% 69.1% EBITDA 198.3 235.6 (15.8%) Normalized Net Income 33.5 81.4 (55.8%) * Core results excludes AstraZeneca/Covis contribution: Deferred Income and Other Income. From...

Almirall, S.A. (ALM) , a global biopharmaceutical company focused on skin health, today announced that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, USA from 9-12 January 2023. Carlos Gallardo, Chairman and CEO of Almirall , is scheduled to give a presentation at 9 am Pacific Standard Time (6pm CET) on January 10 th , 2023. The presentation will be available at https://www.almirall.com/investors Almirall’s executive team will host...

Almirall, S.A. (ALM) , a global biopharmaceutical company focused on skin health, today announced that it is participating in FACILITATE , ( F r A mework for C l I nica L tr I al participants’ da TA reutilization for a fully T ransparent and E thical ecosystem) a patient-driven Innovative Medicines Initiative (IMI) project aimed to create a framework for access and reutilization of clinical trial participant data for a fully compliant and ethical ecosystem . FACILITATE main objective is to...

Almirall, S.A. (ALM) , the global biopharmaceutical company based in Barcelona, has announced its 9M 2022 financial results. Financial highlights (€ rounded million) 9M 2022 9M 2021 Variation Core Net Sales* 633.8 601.7 5.3% Core EBITDA* 134.0 164.2 (18.4%) Total EBITDA 146.4 181.2 (19.2%) Net Income 10.9 (39.4) n.m Normalized Net Income 32.7 61.5 (46.8%) * Core results excludes AstraZeneca and Covis contribution: Deferred Income and Other Income. From 2022 onwards, there is no difference...

Almirall opens a new subsidiary for the Czech Republic and Slovakia PR Newswire BARCELONA, Spain, Nov. 8, 2022 The company is appointing David Festa as General Manager of the Czech Republic and Slovakia affiliate The new affiliate responds to Almirall's expansion strategy to support the company's gradual growth and to offer its treatments to a wider number of people living with dermatological diseases Almirall will start commercializing Ilumetri ® ▼ (tildrakizumab) in these two countries for...

...

Almirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for lebrikizumab in atopic dermatitis PR Newswire BARCELONA, Oct. 28, 2022 Approval in Europe is expected in the second half of 2023 The EMA application is based on the analysis of Phase III studies ADvocate 1&2 and ADhere Atopic dermatitis (AD) is a chronic, inflammatory skin disease. Up to 4.4% of adults in EU are affected, the prevalence appears to have increased over the past decades [1] , [2] BARCELONA...

Almirall, LLC, a global biopharmaceutical company focused on skin health, is excited to announce the release of its privately funded PROSES study at this year’s Fall Clinical Dermatology Conference® in Las Vegas, Nevada, October 20-23, 2022. Over the course of the 12-week study, patients with moderate to severe non-nodular acne vulgaris showed a significant improvement in certain health-related quality of life measures during treatment with sarecycline. “This important real-world study...

Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, and Simcere Pharmaceutical Group （2096.HK), an innovation and R&D-driven pharmaceutical company; today announced that they have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune drug candidate, SIM0278. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220929005090/en/ Under the agreement,...

Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc PR Newswire NANJING, China, Sept. 28, 2022 Simcere will receive a $15 million upfront payment, and up to $492 million in development and commercial milestone payments considering successful achievements in several indications, with an important part as sales milestones, as well as up to low double-digit tiered royalties based upon future global sales Under the agreement, Almirall will be granted an exclusive right to develop...

Almirall: Tildrakizumab is the first and only IL-23p19 inhibitor to demonstrate meaningful sleep improvement in people living with psoriasis PR Newswire BARCELONA , Spain, Sept. 14, 2022 The phase IV study TRIBUTE demonstrated that tildrakizumab is the first and only IL-23p19 inhibitor to improve sleep impairment in psoriasis patients after 24 weeks of treatment in conditions close to clinical practice 1 Patients also reported significant improvement in burdensome symptoms of psoriasis such as...